|Bid||0.00 x 1800|
|Ask||0.00 x 1200|
|Day's Range||56.57 - 58.81|
|52 Week Range||17.51 - 111.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||101.56|
NEW YORK, NY / ACCESSWIRE / June 18, 2018 / U.S. market plunged on Friday, but well-off session lows as investors appeared to look at previous signs of escalating trade tension between Washington and Beijing. ...
The S&P 500’s top gainers on June 14 were: Nektar Therapeutics (NKTR) gained 5.5%. Royal Caribbean Cruises (RCL) gained 5.1%. Comcast Corp A (CMCSA) gained 4.6%. Discovery Comm A (DISCA) gained 4.5%. Incyte (INCY) gained 4.4%. Nektar Therapeutics
SAN FRANCISCO, June 14, 2018 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) in San Diego, California. "We are privileged that these meaningful new data from our clinical trials, as well as our translational research, were recognized for oral presentation at the prestigious CPDD meeting," said Steve Doberstein, Ph.D., Senior Vice President and Chief Research and Development Officer of Nektar Therapeutics.
Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...
Nektar Therapeutics (NKTR) went on a rollercoaster ride last week, and is down again today, following a downgrade, along with much of the rest of biotech. First, it notched a painful 40% plunge last Monday, in reaction to a presentation detailing its experimental drug NKTR-214 at a meeting at the American Society of Clinical Oncology, which didn't live up to high expectations. Then, it bounced back for two days of gains of 6.5% and 7.2% on Tuesday and Wednesday, respectively, before the optimism ran out and it fell more than 11% on Thursday. All of that movement means that while the intensely volatile shares are up 185% in the past 12 months, they've fallen more than 12% year to date. Today, the shares are down again, after H.C. Wainwright threw in the towel and downgraded Nektar to Neutral with a $54 price target.
The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves . Nektar Therapeutics (NASDAQ: NKTR ) slumped about 42 percent, while Deciphera Pharmaceuticals ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
The S&P 500’s top losses on June 7 were: Nektar Therapeutics (NKTR) declined 11.7%. Seagate Technology (STX) declined 5.9%. Lam Research (LRCX) declined 5.4%. J.M. Smucker (SJM) declined 5.4%. Advanced Micro Devices (AMD) declined 5%. Nektar Therapeutics
Small companies are setting a record pace on Wall Street this year, but many investors are missing out on the cream thanks to a divergence between the two main benchmarks that define the sector for fund managers. and have left the S&P 500 well behind in performance terms so far this year: the S&P 500’s 3.6 per cent rise pales when compared with 10.6 per cent for the S&P 600 index and 8.6 per cent for the Russell 2000, the two main indices tracking small-caps. The performance of these benchmarks affirms the over-arching bull case on small-caps generally, but why is the S&P 600 outperforming the Russell 2000?
Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.
The Dow Jones industrial Average gained nearly 100 points even as everything else fell apart. The Nasdaq Composite, which had been rallied for four days, sank 0.7% to 7635.07, while the S&P 500 dipped 0.1% to 2770.37. "The Dow continued higher, but the NASDAQ Composite took a hit," writes Todd Market Forecast's Stephen Todd.
The S&P 500’s top gainers on June 6 were: Nektar Therapeutics (NKTR) gained 7.2%. Equifax (EFX) gained 6.1%. Dish Network (DISH) gained 5.8%. Devon Energy (DVN) gained 5.6%. Adv Micro Devices (AMD) gained 5.5%. Nektar Therapeutics
Nektar Therapeutics (NKTR) used up $52.5 million on operating activities in Q1 2018 compared with $34.6 million in Q1 2017. Operating cash flow in Q1 2018 included $57.5 million of net operating cash use along with $5 million for interest payments on Nektar’s senior secured notes partially offset by the receipt of a milestone payment of $10 million from Baxalta. Nektar expects cash used in operating activities in fiscal 2018 to increase as compared with fiscal 2017 mainly as a result of higher research and development expenses.
Nektar Therapeutics’ (NKTR) cost of goods sold increased from $6.1 million in Q1 2017 to $6.6 million in Q1 2018. This increase was due to Nektar’s clinical development of NKTR-214, NKTR-181, and NKTR-262 and preclinical activities for NKTR-255. Nektar Therapeutics expects research and development expenses to increase significantly in fiscal 2018 as compared to fiscal 2017 mainly on account of the development of NKTR-214 under its collaboration agreement with Bristol-Myers Squibb.
The Dow Jones Industrial Average gained more than 300 points today. Today, it was the Dow's turn. The Dow got a huge lift from Boeing (BA), which rose 3.2% to $371.56, and added 78.91 points to the price-weighted benchmark.
Nektar Therapeutics popped for the second day running Wednesday as it tried to recover from a melanoma presentation with Bristol-Myers Squibb.
In the first quarter of 2018, Nektar Therapeutics (NKTR) generated total revenues of $38 million compared with $24.7 million in the first quarter 2017. Nektar’s licensing and collaboration revenues rose more than 100% from $6 million in Q1 2017 to $13.7 million in Q1 2018. This increase was primarily due to the recognition of a milestone payment of $10 million received by Nektar in March 2018 resulting from the marketing authorization of Adynovi in the European Union in January 2018.
Nektar Therapeutics (NKTR) is a San-Francisco-headquartered biopharmaceutical company with a focus on research. It is developing drug candidates that make use of Nektar’s advanced polymer conjugate technology platforms. Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating, while one analyst has given it a “hold” rating.
After a stellar rise in the past 12 months, Nektar Therapeutics (NKTR) stock fell more than 40% on June 4, which wiped out close to $6 billion of the company’s market cap. This drop was after Bristol Myers Squibb (BMY) and Nektar reported preliminary results from the currently ongoing phase one and two study for NKTR-214 in combination with Opdivo for treating patients with stage four metastatic melanoma, renal cell carcinoma, and urothelial cancers. The price of Bristol-Myers Squibb stock also witnessed selling pressure and fell almost 3% on June 4.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
On June 4, Nektar Therapeutics (NKTR) closed at $52.6—almost 41.8% lower than its previous close of $90.35. The company’s market capitalization fell by ~$6.0 billion to ~$9.0 billion.
Jim Cramer rattles off his take on callers' favorite stocks, including a toymaker recovering from Toys R Us' bankruptcy.